967.8000 -21.40 (-2.16%)
NSE Aug 14, 2026 15:31 PM
Volume: 168.4K
 

967.80
-2.16%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading below all available SMAs
More from Strides Pharma Science Ltd.
Recommended